3 people (two women and a man) at the gym doing a spin class on indoor bicycles
Factor VIII levels at 43%, 4 days after infusion
Hypothetical patient and scenario
Factor VIII levels at 43%, 4 days after infusion
Hypothetical patient and scenario

Factor up with an established safety profile

Understanding Inhibitors

Your body can also make antibodies called inhibitors against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

Your body can also make antibodies called inhibitors against ALTUVIIIO. This can stop ALTUVIIIO from working properly. Your healthcare provider may give you blood tests to check for inhibitors.

0
Factor VIII inhibitors or serious allergic reactions were reported in XTEND-1 and XTEND-Kids studies

In the postmarketing setting, people taking ALTUVIIIO have reported:

Factor VIII inhibitors*
Call your healthcare provider or treatment facility if your Factor VIII therapy does not seem to be working, as this may be a sign of inhibitor development.
Call your healthcare provider or treatment facility if your Factor VIII therapy does not seem to be working, as this may be a sign of inhibitor development.
Serious allergic reactions
Call your healthcare provider or go to the emergency room right away if you experience any of the signs of an allergic reaction, which include rash, hives, itching, facial swelling, chest tightness, or wheezing.
Call your healthcare provider or go to the emergency room right away if you experience any of the signs of an allergic reaction, which include rash, hives, itching, facial swelling, chest tightness, or wheezing.

In 233 people across both the clinical studies:

  • 15% experienced headache (35 people)
  • 13% experienced joint pain (31 people)
  • 4% experienced fever (10 people)
  • 4% experienced pain in extremities (10 people)
  • 4% experienced back pain (9 people)
  • 3% experienced vomiting (7 people)
  • 15% experienced headache (35 people)
  • 13% experienced joint pain (31 people)
  • 4% experienced fever (10 people)
  • 4% experienced pain in extremities (10 people)
  • 4% experienced back pain (9 people)
  • 3% experienced vomiting (7 people)
*
The potential for inhibitor development is a known risk that can occur with any factor replacement therapy, including ALTUVIIIO.
Included participants of the XTEND-1 and XTEND-Kids studies.
Find your CoRe Manager and connect today!
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.
CoRe manager icon